| | Business Summary | | Calypte
Biomedical
Corporation
is
engaged
in
the
development
of
a
urine-based
screening
test
for
the
detection
of
antibodies
to
the
Human
Immunodeficiency
Virus,
Type-1
(HIV-1),
the
putative
cause
of
Acquired
Immunodeficiency
Syndrome
(AIDS).
The
Company
has
integrated
several
proprietary
technologies
to
develop
a
test
that,
in
clinical
trials,
detected
the
presence
of
HIV
antibodies
in
urine
with
99.7%
sensitivity
in
subjects
known
to
be
HIV-1
infected,
as
identified
through
blood-based
(serum/plasma)
screening
tests.
The
Company
estimates
that
the
cost
of
collecting,
handling,
testing
and
disposing
of
urine
specimens
will
be
significantly
less
than
that
of
blood
specimens. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | CALY
is
engaged
in
the
development
of
a
urine-based
screening
test
for
the
detection
of
antibodies
to
the
Human
Immunodeficiency
Virus,
Type-1,
the
putative
cause
of
AIDS.
For
the
six
months
ended
6/30/01,
revenues
rose
60%
to
$3
million.
Net
loss
applicable
to
Common
and
before
extraordinary
item
rose
20%
to
$6.5
million.
Revenues
reflect
higher
supplemental
HIV-1
urine,
antigen
and
urine
and
serum
western
blot
test
sales.
Higher
loss
reflects
higher
SGA
costs
and
$1.3
million
in
financing
charges. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Collins, 67
Chairman,
Sec. | $70K | $51K | Nancy Katz, 42
Pres,
CEO, Chief Financial Officer, Director | 340K | 40K | Howard Urnovitz, Ph.D., 47
CSO,
Director | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/c/caly.ob.gif)